• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Two Vaccines Against RSV in Older Adults Approved One Month Apart: It Happened in 2023

News
Slideshow

The seasonal respiratory syncytial virus, which claims between 6000 and 10 000 older adult lives each year, will now face significant barriers to spread in this vulnerable population the US.

The short slide show that follows provides snapshots of the headline news stories posted on Patient Care® in 2023 that traced the clinical trials and approval process for GKS's RSVPreF3 (Arexvy) and Pfizer's RSVPreF (Abrysvo).

Related Content
Shingrix Nearly 80% Effective Against Shingles in Older Adults up to 11 Years Post-Vaccination / Image credit: ©Sherry Young/AdobeStock

Shingrix Nearly 80% Effective Against Shingles in Older Adults up to 11 Years Post-Vaccination

April 18th 2024
Article

Vaccine efficacy remained high at 82% at year 11 following vaccination, according to new long-term data.

RSV Disease Severity Comparable to Unvaccinated COVID-19, Flu: Daily Dose / image credit: ©New Africa/AdobeStock

RSV Disease Severity Comparable to Unvaccinated COVID-19, Flu: Daily Dose

April 18th 2024
Article

Your daily dose of the clinical news you may have missed.

GSK Announces FDA PDUFA Date for 5-in-1 Meningococcal Vaccine / image credit GSK vaccines: ©desertsands/stock.adobe.com

GSK Announces FDA PDUFA Date for 5-in-1 Meningococcal Vaccine Based on Acceptance of BLA

April 17th 2024
Article

The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.

New Research Suggests Cardiac Events are Prevalent in Older Adults Hospitalized with RSV / Image credit: ©Kateryna Kon/AdobeStock

New Research Suggests Cardiac Events are Prevalent in Older Adults Hospitalized with RSV

April 16th 2024
Article

Nearly one-quarter of hospitalized adults aged 50 years and older with RSV experienced an acute cardiac event, according to results of a new study.

RSV Disease Severity Comparable to Unvaccinated COVID-19, Influenza: New Research / image credit older man in hospital ©auremar/stock.adobe.com

RSV Disease Severity Comparable to Unvaccinated COVID-19, Influenza: New Research

April 11th 2024
Article

In adults hospitalized with RSV, odds of severe outcomes, including death, were much higher than for those admitted for, but vaccinated against, COVID-19, flu.

Pfizer: MONeT Study Topline Data Positive for Abrysvo in Adults Aged 18 to 59 Years at High Risk for RSV-LRTD / image credit Pfizer logo: cbies/stock.adobe.com

Pfizer: MONeT Study Topline Data Positive for Abrysvo in Adults Aged 18 to 59 Years at High Risk for RSV-LRTD

April 9th 2024
Article

Pfizer plans to submit the phase 3 MONeT data to regulatory bodies in support of an expanded label for Abrysvo to include adults aged 18 to 59, the company said.

© 2024 MJH Life Sciences

All rights reserved.